Abdel-Aziz, M.I.* ; Hashimoto, S.* ; Neerincx, A.H.* ; Haarman, E.G.* ; Cecil, A. ; Lintelmann, J. ; Witting, M. ; Hauck, S.M. ; Kerssemakers, N.* ; Verster, J.C.* ; Bang, C.* ; Franke, A.* ; Dierdorp, B.S.* ; Dekker, T.J.* ; Metwally, N.K.A.* ; Duitman, J.W.* ; Lutter, R.* ; Gorenjak, M.* ; Toncheva, A.A.* ; Kheiroddin, P.* ; Harner, S.* ; Brandstetter, S.* ; Wolff, C.* ; Corcuera-Elosegui, P.* ; López-Fernández, L.* ; Perez-Garcia, J.* ; Almeida, M.M.* ; Sardón-Prado, O.* ; Pino-Yanes, M.* ; Potocnik, U.* ; Kabesch, M.* ; Vijverberg, S.J.H.* ; Kraneveld, A.D.* ; Maitland-van der Zee, A.H.*
     
 
    
        
Metabotypes are linked to uncontrolled childhood asthma, gut microbiota, and systemic inflammation.
    
    
        
    
    
        
        J. Allergy Clin. Immunol. 156:339-351 (2025)
    
    
    
		
		
			
				BACKGROUND: Childhood asthma has been linked to distinct metabolomic profiles. OBJECTIVE: To identify phenotypes (metabotypes) in children with moderate-to-severe asthma through integrative fecal and serum metabolome analysis. METHODS: Children from the Systems Pharmacology Approach to Uncontrolled Pediatric Asthma cohort with Global Initiative for Asthma treatment step ≥3 were recruited. Asthma control was defined by the Asthma Control Test and annual exacerbation history. Targeted metabolomics profiling of feces and serum was performed using liquid chromatography and flow injection electrospray ionization-triple quadrupole mass spectrometry. Similarity Network Fusion integrated fecal and serum metabolome profiles, followed by spectral clustering. Clusters were analyzed for differences in asthma characteristics, food diaries, fecal microbiota composition, and levels of serum inflammatory markers and blood cells. RESULTS: Integrative fecal and serum metabolome analysis of 92 children with moderate-to-severe asthma (median age: 11.5 years, 34% female) revealed three metabotypes. Metabotype1 had the lowest percentage of allergic rhinitis, with elevated serum ceramides and triglycerides. Metabotype2 had higher odds of asthma control, the highest percentage of children with ≥4 months of breastfeeding, reduced sugar intake, lowest levels of blood neutrophils and serum inflammatory markers, and with elevated serum acylcarnitines and ω-3 fatty acids. Metabotype3 included the highest percentage of uncontrolled asthma patients, with decreased serum cholesteryl esters, phosphatidylcholines, and sphingomyelins, elevated fecal amino acids, and reduced fecal microbiota diversity. CONCLUSIONS: Metabotypes in children with moderate-to-severe asthma are linked to asthma control, distinct fecal microbiota and systemic inflammatory patterns. The findings suggest that metabotyping can be valuable in precision medicine approaches for asthma.
			
			
				
			
		 
		
			
				
					
					Impact Factor
					Scopus SNIP
					Web of Science
Times Cited
					Scopus
Cited By
					
					Altmetric
					
				 
				
			 
		 
		
     
    
        Publikationstyp
        Artikel: Journalartikel
    
 
    
        Dokumenttyp
        Wissenschaftlicher Artikel
    
 
    
        Typ der Hochschulschrift
        
    
 
    
        Herausgeber
        
    
    
        Schlagwörter
        Gut Microbiota ; Inflammatory Markers ; Metabotyping ; Moderate-to-severe Childhood Asthma ; Personalized Medicine
    
 
    
        Keywords plus
        
    
 
    
    
        Sprache
        englisch
    
 
    
        Veröffentlichungsjahr
        2025
    
 
    
        Prepublished im Jahr 
        0
    
 
    
        HGF-Berichtsjahr
        2025
    
 
    
    
        ISSN (print) / ISBN
        0091-6749
    
 
    
        e-ISSN
        1097-6825
    
 
    
        ISBN
        
    
 
    
        Bandtitel
        
    
 
    
        Konferenztitel
        
    
 
	
        Konferzenzdatum
        
    
     
	
        Konferenzort
        
    
 
	
        Konferenzband
        
    
 
     
		
    
        Quellenangaben
        
	    Band: 156,  
	    Heft: 2,  
	    Seiten: ,  
	    Artikelnummer: 339-351 
	    Supplement: ,  
	
    
 
  
        
            Reihe
            
        
 
        
            Verlag
            Elsevier
        
 
        
            Verlagsort
            Amsterdam [u.a.]
        
 
	
        
            Tag d. mündl. Prüfung
            0000-00-00
        
 
        
            Betreuer
            
        
 
        
            Gutachter
            
        
 
        
            Prüfer
            
        
 
        
            Topic
            
        
 
	
        
            Hochschule
            
        
 
        
            Hochschulort
            
        
 
        
            Fakultät
            
        
 
    
        
            Veröffentlichungsdatum
            0000-00-00
        
 
         
        
            Anmeldedatum
            0000-00-00
        
 
        
            Anmelder/Inhaber
            
        
 
        
            weitere Inhaber
            
        
 
        
            Anmeldeland
            
        
 
        
            Priorität
            
        
 
    
        Begutachtungsstatus
        Peer reviewed
    
 
     
    
        POF Topic(s)
        30505 - New Technologies for Biomedical Discoveries
30203 - Molecular Targets and Therapies
    
 
    
        Forschungsfeld(er)
        Enabling and Novel Technologies
    
 
    
        PSP-Element(e)
        A-630710-001
G-505700-001
    
 
    
        Förderungen
        Spanish Ministry of Science, Innovation, and Universities
Ministry of Higher Education (Egypt)
Longfonds, Stichting Astma Bestrijding, and Amsterdam Public Health Institute (Netherlands)
Instituto de Salud Carlos III through Strategic Action for Health Research (AES) and European Community within the Active and Assisted Living Program framework
German Ministry of Education and Research (BMBF)
Ministry of Higher Education, Science and Innovation of the Republic of Slovenia (MVZI)
Netherlands Organisation for Health Research and Development (ZonMw)
    
 
    
        Copyright
        
    
 	
    
    
    
    
    
        Erfassungsdatum
        2025-05-10